INJECTABLES EXCELLENCE
DEAD

Serial Number

77256646

Owner

SAGENT HOLDING CO.

Attorney

Marcia Ireland Rosenfeld

Filing Date

Aug 16, 2007

Add to watchlist:

No watchlists yet
View on USPTO

INJECTABLES EXCELLENCE Trademark

Serial Number: 77256646

INJECTABLES EXCELLENCE is a trademark filed by SAGENT HOLDING CO. on August 16, 2007. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

SAGENT HOLDING CO. (19 trademarks)

UGLAND HOUSE, SOUTH CHURCH STREET
GEORGETOWN , KY

Entity Type: 03

Trademark Details

Filing Date

August 16, 2007

Registration Date

Not Registered

Published for Opposition

July 8, 2008

Goods & Services

Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-infectives, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, cardiovasculars, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, vascular targeting agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases; injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of allergies; injectable drugs and therapeutic solutions for the treatment of infections; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Oct 31, 2011 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 31, 2011 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2011 EXRA
SOU EXTENSION 5 GRANTED
Apr 5, 2011 EX5G
SOU EXTENSION 5 FILED
Mar 28, 2011 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 28, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 5, 2010 EXRA
SOU EXTENSION 4 GRANTED
Oct 4, 2010 EX4G
SOU EXTENSION 4 FILED
Sep 30, 2010 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 30, 2010 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 30, 2010 EXRA
SOU EXTENSION 3 GRANTED
Mar 29, 2010 EX3G
SOU EXTENSION 3 FILED
Mar 25, 2010 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 25, 2010 EEXT
SOU EXTENSION 2 GRANTED
Oct 14, 2009 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 13, 2009 AITU
SOU EXTENSION 2 FILED
Sep 30, 2009 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 30, 2009 EEXT
SOU EXTENSION 1 GRANTED
Mar 30, 2009 EX1G
SOU EXTENSION 1 FILED
Mar 30, 2009 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 30, 2009 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Sep 30, 2008 NOAM
PUBLISHED FOR OPPOSITION
Jul 8, 2008 PUBO
NOTICE OF PUBLICATION
Jun 18, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 4, 2008 PREV
ASSIGNED TO LIE
Jun 3, 2008 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2008 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 27, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 27, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 27, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 27, 2007 GNRN
NON-FINAL ACTION E-MAILED
Nov 27, 2007 GNRT
NON-FINAL ACTION WRITTEN
Nov 27, 2007 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 27, 2007 GNRN
NON-FINAL ACTION E-MAILED
Nov 27, 2007 GNRT
NON-FINAL ACTION WRITTEN
Nov 27, 2007 CNRT
ASSIGNED TO EXAMINER
Nov 26, 2007 DOCK
NEW APPLICATION ENTERED
Aug 20, 2007 NWAP